Wells Fargo Initiates Oxigene

Analyst Paul Keough says the oncology research company's vscular targeting agents has breakthrough potential that could gain widespread use in large cancer markets

Wells Fargo initiates Oxigene Inc. (OXGN ) coverage with buy.

Analyst Paul Keough believes Oxigene's approach to vessel disruption, called vascular targeting agents (VTAs), has breakthrough potential in numerous cancer indications as a complementary add-on treatment to chemotherapy, radiation therapy, and anti-angiogenesis agents.

He believes Oxigene leads the clinical race for VTAs, which could eventually gain widespread use in large cancer markets.

Likely as partnership, Keough estimates the company could have sales potential of $1 billion to $2 billion. He has a $7 target.

Before it's here, it's on the Bloomberg Terminal. LEARN MORE